Dr. Sara Zarnegar-Lumley, MD
Claim this profileVanderbilt University/Ingram Cancer Center
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
10 reported clinical trials
37 drugs studied
Area of expertise
1Leukemia
BCR-ABL1 fusion positive
ABL-class fusion positive
Philadelphia chromosome positive
2Lymphoblastic Leukemia-Lymphoma
BCR-ABL1 fusion positive
ABL-class fusion positive
Philadelphia chromosome positive
Affiliated Hospitals
Clinical Trials Sara Zarnegar-Lumley, MD is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Diagnostic Testing
for Pediatric Leukemia
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Recruiting1 award Phase 1 & 211 criteria
More about Sara Zarnegar-Lumley, MD
Clinical Trial Related4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Sara Zarnegar-Lumley, MD has experience with
- Methotrexate
- Cytarabine
- Cyclophosphamide
- Dexamethasone
- Pegaspargase
- Prednisolone
Breakdown of trials Sara Zarnegar-Lumley, MD has run
Leukemia
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sara Zarnegar-Lumley, MD specialize in?
Sara Zarnegar-Lumley, MD focuses on Leukemia and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Leukemia has involved BCR-ABL1 fusion positive patients, or patients who are ABL-class fusion positive.
Is Sara Zarnegar-Lumley, MD currently recruiting for clinical trials?
Yes, Sara Zarnegar-Lumley, MD is currently recruiting for 5 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Sara Zarnegar-Lumley, MD has studied deeply?
Yes, Sara Zarnegar-Lumley, MD has studied treatments such as Methotrexate, Cytarabine, Cyclophosphamide.
What is the best way to schedule an appointment with Sara Zarnegar-Lumley, MD?
Apply for one of the trials that Sara Zarnegar-Lumley, MD is conducting.
What is the office address of Sara Zarnegar-Lumley, MD?
The office of Sara Zarnegar-Lumley, MD is located at: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee 37232 United States. This is the address for their practice at the Vanderbilt University/Ingram Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.